English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

CASI Pharmaceuticals Receives Approval From CFDA For Phase II Clinical Trial In China

Mar. 30, 2015

March 30, 2015. CASI Pharmaceuticals has announced the China Food and Drug Administration’s (CFDA) approval to conduct a Phase 2 global clinical trial in ovarian clear cell carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076.

The approval will allow CASI to expand its ongoing Phase 2 OCCC trial currently underway in multiple centers in North America. This is the company’s third approval of a global Phase 2 clinical trial in China.